File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib

TitleNivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Authors
KeywordsHepatocellular carcinoma
Nivolumab
Ipilimumab
Sorafenib
Immune checkpoint inhibitors
Issue Date2021
PublisherTaylor & Francis. The Journal's web site is located at https://www.tandfonline.com/journals/ierh20
Citation
Expert Review of Gastroenterology and Hepatology, 2021, v. 15 n. 6, p. 589-598 How to Cite?
AbstractIntroduction: The systemic treatment of advanced, unresectable hepatocellular carcinoma (HCC) has undergone an evolution in recent years. In March 2020, a combination of nivolumab and ipilimumab was approved by the FDA for treatment of patients with advanced HCC who received prior sorafenib. This was based on the results of the phase I/II CheckMate-040 cohort 4 trials, which showed a promising overall response rate and encouraging overall survival with a manageable safety profile. Areas covered: This article reviews the pharmacology, efficacy and safety of nivolumab-ipilimumab in advanced HCC with prior sorafenib. Other existing systemic treatment options for advanced HCC will be described and compared to nivolumab-ipilimumab. Impact of different dose regimes, ongoing research and future developments of nivolumab-ipilimumab will be discussed. We focus on the analysis from the aforementioned CheckMate-040 cohort 4 registration trial. Expert opinion: The approval of nivolumab-ipilimumab in the second-line treatment of advanced HCC by the FDA is an important development for treatment of advanced HCC. However, further investigations are needed to optimize dosing regimens and explore the use of nivolumab-ipilimumab in other combinations and settings.
Persistent Identifierhttp://hdl.handle.net/10722/304986
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 1.090
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTsang, J-
dc.contributor.authorWong, JSL-
dc.contributor.authorKwok, GGW-
dc.contributor.authorLi, BCW-
dc.contributor.authorLeung, R-
dc.contributor.authorChiu, J-
dc.contributor.authorCheung, TT-
dc.contributor.authorYau, T-
dc.date.accessioned2021-10-05T02:38:06Z-
dc.date.available2021-10-05T02:38:06Z-
dc.date.issued2021-
dc.identifier.citationExpert Review of Gastroenterology and Hepatology, 2021, v. 15 n. 6, p. 589-598-
dc.identifier.issn1747-4124-
dc.identifier.urihttp://hdl.handle.net/10722/304986-
dc.description.abstractIntroduction: The systemic treatment of advanced, unresectable hepatocellular carcinoma (HCC) has undergone an evolution in recent years. In March 2020, a combination of nivolumab and ipilimumab was approved by the FDA for treatment of patients with advanced HCC who received prior sorafenib. This was based on the results of the phase I/II CheckMate-040 cohort 4 trials, which showed a promising overall response rate and encouraging overall survival with a manageable safety profile. Areas covered: This article reviews the pharmacology, efficacy and safety of nivolumab-ipilimumab in advanced HCC with prior sorafenib. Other existing systemic treatment options for advanced HCC will be described and compared to nivolumab-ipilimumab. Impact of different dose regimes, ongoing research and future developments of nivolumab-ipilimumab will be discussed. We focus on the analysis from the aforementioned CheckMate-040 cohort 4 registration trial. Expert opinion: The approval of nivolumab-ipilimumab in the second-line treatment of advanced HCC by the FDA is an important development for treatment of advanced HCC. However, further investigations are needed to optimize dosing regimens and explore the use of nivolumab-ipilimumab in other combinations and settings.-
dc.languageeng-
dc.publisherTaylor & Francis. The Journal's web site is located at https://www.tandfonline.com/journals/ierh20-
dc.relation.ispartofExpert Review of Gastroenterology and Hepatology-
dc.subjectHepatocellular carcinoma-
dc.subjectNivolumab-
dc.subjectIpilimumab-
dc.subjectSorafenib-
dc.subjectImmune checkpoint inhibitors-
dc.titleNivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib-
dc.typeArticle-
dc.identifier.emailLi, BCW: bryanli@hku.hk-
dc.identifier.emailChiu, J: jwychiu@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityChiu, J=rp01917-
dc.identifier.authorityCheung, TT=rp02129-
dc.identifier.authorityYau, T=rp01466-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/17474124.2021.1899808-
dc.identifier.pmid33666530-
dc.identifier.scopuseid_2-s2.0-85102929304-
dc.identifier.hkuros326210-
dc.identifier.volume15-
dc.identifier.issue6-
dc.identifier.spage589-
dc.identifier.epage598-
dc.identifier.isiWOS:000630670200001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats